BCG vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

BCG vaccine is a vaccine indicated in the prevention of tuberculosis and the treatment of non-invasive urothelial bladder cancer.

Generic Name
BCG vaccine
DrugBank Accession Number
DB12768
Background

BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Bacillus calmette-guerin live antigen, unspecified substrain
  • Bacillus Calmette–Guérin (BCG) vaccine
  • BCG
  • BCG vaccine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofNon-invasive bladder urothelial carcinoma•••••••••••••••••• •••••••••••••• ••• ••••••••••
Prevention ofRecurrent superficial bladder cancer•••••••••••••••••••••• •••••••••• ••••••• •••••••••••• ••• ••••••••• •••••••••• ••••••••• ••••••••
Prevention ofTuberculosis (tb)•••••••••••••••••••••
Management ofUrothelial carcinoma recurrent•••••••••••••••••• •••••••••••••• ••• ••••••••••
Treatment ofCarcinoma in situ of urinary bladder•••••••••••••••••••••• •••••••••• ••••••• •••••••••••• ••• ••••••••• •••••••••• ••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when BCG vaccine is combined with Abatacept.
Acetic acidThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetic acid.
Acetyl sulfisoxazoleThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetyl sulfisoxazole.
AcyclovirThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acyclovir.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bcg TherapeuticPowder, for solution27 mg / vialIrrigationConnaught Laboratories Ltd.1990-12-311999-12-03Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Bcg VaccineBCG vaccine (0.75 mg / mL) + Water (2 mL / vial)Liquid; Powder, for solutionIntradermalID Biomedical Corporation of Quebec1991-12-312005-08-03Canada flag

Categories

ATC Codes
L03AX03 — Bcg vaccine
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8VJE55B0VG
CAS number
Not Available

References

General References
  1. TITCK Product Information: Calgevax-BCG (BCG for immunotherapy) powder for intravesical injection [Link]
  2. TITCK Product Information: SII-BCG (BCG vaccine, live, attenuated) powder for suspension for intradermal injection [Link]
PubChem Substance
347911376
RxNav
1344
Wikipedia
BCG_vaccine

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4Active Not RecruitingBasic ScienceBCG Vaccine / Epigenetics / Trained Immunity1somestatusstop reasonjust information to hide
4Active Not RecruitingPreventionCoronavirus as the Cause of Diseases Classified Elsewhere / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1somestatusstop reasonjust information to hide
4CompletedBasic ScienceAdverse Reaction to Vaccine / Immunity, Heterologous / Morbidity;Infant / Mortality, Infant / Trained Immunity / Vaccine Reaction1somestatusstop reasonjust information to hide
4CompletedDiagnosticTuberculosis (TB)1somestatusstop reasonjust information to hide
4CompletedPreventionAbsenteeism / Coronavirus Disease 2019 (COVID‑19) / Morbidity1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravesical30 mg
Powder, for solutionIntravesical1600000000 U
Powder, for suspensionIntravesical1600000000 units
Powder, for solutionIrrigation27 mg / vial
Liquid; powder, for solutionIntradermal
Powder, for suspensionIntravesical
Injection, powder, lyophilized, for solutionIntravesical
Injection, powder, for suspensionIntradermal0.5 mg
PowderIntravesical
Injection, powder, lyophilized, for solutionIntravesical81 mg
Injection, powder, lyophilized, for solutionIntradermal500,000 CFU/0.1ml
InjectionIntradermal0.1 ml
Injection, powder, lyophilized, for suspensionIntravesical40 mg/ml
Injection, powder, for solutionIntravesical
InjectionIntradermal81 mg/1vial
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 21, 2016 00:07 / Updated at May 07, 2024 12:49